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Abstract  
Background and Objective: Atrial fibrillation (AF) represents the most 
common cardiac arrhythmia worldwide; it poses a great burden in terms 
of quality of life reduction and yearly stroke risk. Left atrial appendage 
closure (LAAC) is a stroke prevention strategy that has been proven a 
viable alternative to anti-thrombotic regimens in non-valvular AF 
patients. LAAC can be performed as a stand-alone procedure or alongside 
a concomitant AF trans catheter ablation, in a procedure known as 
“Combined Procedure”. Aim of this study is to summarize the scientific 
evidence backing this combined strategy.  
Methods: We reviewed the whole Medline indexed combined procedure 
literature, to summarize all the combined procedure study data .  
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Results: Nine published studies regarding combined procedure were 
found. Data, aims, and scientific rationales were reported and 
commented. 
Conclusion: LAA combined procedure appears to be a safe and effective 
procedure; a careful patient selection is necessary to maximize its benefit. 
Keywords: Atrial fibrillation • Catheter ablation • Stroke prevention • 
Left atrial appendage • Left atrial appendage closure • Combined ablation 
• Review 
1. Introduction - Left Atrial Appendage Closure in AF treatment  
Non-valvular Atrial Fibrillation (AF) is the most common cardiac 
arrhythmia worldwide, with one in four people expected to develop it 
during their lifetime; it represents a major ischemic stroke risk factor in 
both high and low GPI countries, accounting for 15-20% of all strokes.  
Stroke risk is usually managed through oral anti-coagulant (OAC) drugs 
[vitamin K inhibitors (VKA) or non-vitamin K antagonist oral 
anticoagulants (NOAC)], accordingly to the CHA2DS2-VASc score1. 
Nonetheless, OAC therapy never completely nullifies stroke risk and 
some specific sub-populations may not be eligible for this treatment due 
to high bleeding risk.  
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Following the observation that over 90% of thrombi in AF patients form 
in the left atrial appendage2 (LAA), the concept of percutaneous left atrial 
appendage closure (LAAC) was developed to non-pharmacologically 
address similar conditions.  
In 2009, Holmes D.R, et al developed the PROTECT AF trial3; this 
randomized controlled trial (RCT) compared LAAC using WATCHMAN 
devices with Warfarin treatment; demonstration of non-inferiority was 
achieved, although some concerns over peri-procedural safety arose, due 
to a 8.7% adverse peri-procedural event rate in the intervention arm.  
A second RCT, the PREVAIL trial4, was performed and published by 
Holmes D.R., et al in 2014 to reassess LAAC procedural safety; peri-
procedural adverse events rate dropped (4.2%), due to technical 
innovations and more experienced operators. The 4-year PROTECT-AF 
data analysis showed significantly lower adverse event rates (considering 
both hemorrhagic and ischemic events) in the Watchman versus warfarin 
group, with differences mainly driven by the reduction in hemorrhagic 
strokes (with a non-statistically significant reduction in the stroke rate)5. 
The EWOLUTION registry was then designed to assess the real–world 
impact of LAAC, with more than 1000 patients enrolled and followed-
up6. High rates of acute implantation success (98.5% successful 
occlusion; 91.4% complete occlusion rate and 7.9% leakage < 5 mm rate) 
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were described, with only a 2.7% serious procedure/device related events 
within 7 days from the LAAC7; investigators also reported a 1.1% 
ischemic stroke and bleeding rate8. Although the WATCHMAN device 
was the only one used in those major prospective trials, many other 
devices entered the market and clinical practice9; the Amplatzer Cardiac 
Plug (ACP) was employed as the occluder device in several registries and 
studies10–14. No direct head to head trials between WATCHMAN and 
ACP have been published so far, but no significant differences in clinical 
and procedural outcomes have been reported in those LAAC studies 
including both devices either11–13.  
In current clinical practice, LAAC is accepted as a viable and effective 
option; in recent AF management guidelines, LAAC procedure is 
suggested for patients unsuitable for OACs (e.g. high bleeding risk) or 
who suffered a stroke despite OACs15. The number of LAAC procedure 
performed is rising by the hour and it is expected to continue doing so in 
the years to come. 
Alongside the LAAC as a stand-alone procedure, many groups have 
published data about the so-called “combined procedure”, consisting of 
LAAC alongside a contextual AF catheter ablation (CA).  
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In this article we sought to summarize the current literature regarding the 
combined AF ablation and LAAC procedure, its advantages and 
disadvantages, as well as to address the future perspectives of this 
methodic.  
2. Combined Procedure Proof-Of-Concept:  
The idea of combined procedure was first introduced in 2012, when 
Swaans M. et al presented a case series of 30 combined procedures, 
involving LAAC alongside pulmonary vein isolation (PVI), performed 
with phased radiofrequency as energy source16. LAAC procedure was 
performed under continuous trans-esophageal echography (TEE) and 
fluoroscopy guidance. A 100% LAA closure success rate was achieved 
acutely, with 3 (10%) minor bleeding as peri-procedural complications. 
No major (> 5 mm) leakages and only a 23% of patients with minimal (< 
5 mm) residual flow were found at the 60-day follow up TEE; these 
occlusion rates improved to a 93% complete occlusion rate at the 6-
month follow up visit, resulting in an 80% VKA discontinuation rate. The 
freedom from arrhythmia rate reported at 12 months was 70%.  
The authors observed that performing LAAC after CA did not appear to 
exceedingly prolong procedural time and the long term combined 
procedure AF recurrence rates were comparable to the one achieved by 
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CA alone at their institution; no strokes were witnessed over a 12-month 
follow up. 
In conclusion, authors suggested the combined approach would be 
especially helpful in AF patients with both high stroke and bleeding risk, 
as well as in patients with a low expected long term efficacy of ablation 
alone: by closing the LAA, OAC could be in fact withhold upon AF 
recurrence. Another preliminary experience with 26 patients enrolled and 
similar results was described by Walker B., et al in the same year17. These 
first experience represented a refined way to address AF symptoms, 
reducing at the same time stroke risk and the need for OACs. 
3. Early Experiences:  
In 2015, Alipour A. et al furthermore expanded the combined procedure 
evidence, by publishing a prospective study including a larger sample of 
62 patients18. In this study, PVI energy source was phased RF and LAAC 
was performed using WATCHMAN devices. The larger sample size 
allowed a more reliable description of the peri-procedural adverse events: 
in this cohort, 5 (8.1%) patients developed a minor peri-procedural 
bleeding, with nor pericardial effusions neither strokes. Although the 
adverse event rate did not result much lower to the one reported in the 
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first experiences, all the encountered peri-procedural events resulted mild 
in their gravity and posed no real danger to the patient.  
This study gave valuable data about the combined procedures long term 
follow up, reporting a 38 [25 – 45] months as median follow up time; 
95.2% of patients presented satisfactory LAA occlusion rate, with a 45% 
rate of < 5 mm leakages and 1 (1.6%) device embolization. Over 58% of 
the population did not experience AF recurrences and the reported OAC 
discontinuation rate was 78%; 3 (4.8%) strokes were reported (1.7% 
year/stroke rate; 74% risk reduction from expected). Authors speculated 
that a quota of those strokes may be due to carotidal atherosclerotic 
plaques and not AF-related; however, 2 (3.2%) strokes interested patients 
with a < 5 mm leakages and, although a previous PROTECT AF 
retrospective analysis did not establish a relation between minimal flow 
leakages and stroke risk19, the AF etiology could not be ruled out.  
In the same year, Calvo N., et al. published a prospective studying 
describing 35 combined procedures performed with a mixture of 
WATCHMAN and ACP as occluder devices13. The main indication for 
LAAC was high bleeding risk (48% of patients) and the combined 
procedure took place to discontinue long term OACs, regardless of 
arrhythmia recurrences.  
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This study reported several interesting points: 1) At 13 months, 78% of 
patients were free from AF, despite elevated rates of persistent and long 
standing persistent AF patterns; 2) For the first time, the main indication 
for combined procedure was a high bleeding risk; the PROTECT-AF trial 
established LAAC significant superiority over Warfarin in bleeding 
adverse event reduction: the combined procedure was used accordingly to 
that indication; 3) The intra-procedural adverse event rate in this study 
was very high (8.5%); authors attributed it to the longer learning curve 
required by using a mixture of devices instead than a single one.  
At the end of 2015, combined procedure had emerged as a reliable and 
effective in reducing stroke and bleeding risk procedure; many dedicated 
team were developed, to overcome the learning curve effect and lower 
the peri-procedural risks. A paper from Phillips K., et al. summarized this 
experience, presenting 98 combined procedures performed with RF, with 
similar results at a long term follow up20. 
4. “Here Comes The Ice”: Cryo-energy Combined Procedures 
In 2016, cryo-energy instead of RF as energy source was introduced in 
combined procedure by Fassini G., et al. They reported the safety and 
feasibility of the technique using cryo-energy delivered through 1st and 
2nd generation cryo-balloons in a high-stroke risk population. In their 
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pilot study, 35 patients were enrolled and underwent cryo-balloon PVI 
alongside WATCHMAN or ACP LAAC; peri-procedural reported 
adverse event rate and procedural time resulted comparable to previous 
RF CA combined procedure experiences.  
At a 24 ± 12 month follow up, a 80% freedom from arrhythmias was 
achieved; a high long term complete LAA sealing (92%) was described, 
with all other patients experiencing a < 5 mm leakage. These results were 
then confirmed at a longer follow up and in a larger patient sample by a 
second study from the same group21. Combined procedure feasibility, 
safety and effectiveness regardless the energy source for PVI (RF or 
Cryo) and device brand choice was demonstrated with this experience; no 
evidence of superiority of an energy source on the other are to date 
available, leaving to the operator the option (and the burden) of the 
choice. 
5. The Combined Procedure Nowadays 
All those small/medium- sample sized experience data were summarized 
by two analyses published in 2018 by an investigation group led by L. 
Boersma.  
Phillips K., et al22 assessed combined procedure 30-day outcomes by 
pooling data from two large prospective multicenter LAAC registries 
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(EWOLUTION and WASP). Their analysis included 139 combined 
procedures, performed with irrigated RF by experienced operators and 
certified device implanters: acute success rate was confirmed to be 100%, 
with a 97% complete appendage occlusion rate, almost always without 
the need of device resizing or recapturing.  
Three major points were highlighted: 1) In the hands of experienced 
operators, the encountered pericardial effusion rate was 1.4%, with no 
peri-procedural stroke or deaths. These outcomes resulted consistent with 
a previous EWOLUTION registry analysis7, demonstrating that with new 
LAA device implanting techniques a low peri-procedural adverse event 
rate can be achieved even in high risk patient groups during combined 
procedure. The pooled data on peri-procedural adverse event rate in 
combined procedures resulted even lower than complication rates 
reported in worldwide AF ablation surveys23, stating that for high volume 
operators adding LAAC to an AF ablation procedure does not increase 
the chance of complications.  
2) A 2-month post procedural OAC regimen has been considered routine 
protocol from the start of the combined procedure experience, with VKAs 
being the employed drug of choice. In this analysis, NOACs as discharge 
therapy were analyzed on a large sample and found safe and compatible 
with the WATCHMAN prosthetic material: the reported 30-day bleeding 
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adverse event rate (2.9%) resulted equally divided between VKA and 
NOACs users and consistent with contemporary results experienced in 
CA PVI alone24.  
3) New peri-device leaks were noted at the first TEE follow up (from 
2.9% intra or post-procedure to 39%); these leaks resolved or reduced in 
size over the following follow-up months. Authors reported this 
phenomenon as experienced in many previous LAAC trials3,4 and it was 
attributed to a mix of factors: a circular device and non-circular LAA 
mismatch, edema masking LAA size and causing mismatch at implant 
time, and a potential atrial remodeling. 
A few months later, a prospective multicenter trial by Wintgens L., et al25 
described the largest combined procedure population sample (349 
patients) with the longest median follow up (34.5 months) to date ever 
presented. The low peri-procedural adverse event rate previously reported 
was confirmed: the peri-procedural adverse (considering pericardial 
effusion, air emboli and stroke) event rate was 2.2%, much lower than 
those in PROTECT-AF, PREVAIL, and EWOLUTION trials. 
Furthermore, most of the complications observed resulted femoral-
access-derived and not device-related; these results supported the 
previous studies, showing substantial improvement in safety with 
increasing experience of the combined procedure team.  
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Rates of complete and satisfactory LAA sealing were comparable to 
those described by Phillips K., et al22, both in acute and at follow up, de 
facto confirming their previous assessment. An annualized stroke and 
major bleeding rate of only 0.7% and 1.1%, respectively, were observed 
in this population, regardless of a 51% rate of arrhythmic recurrences; the 
effectiveness of combined procedure was assessed in a 75% stroke and 
71% bleeding risk reduction respectively, from CHAD-VASC and HAS-
BLED prediction in the population. A 84.9% long time OACs 
discontinuation rate was achieved in this experience.  
6. LAA Contemporary Occlusion and Isolation  
Over the years, several studies have described LAA electrical activity as 
one of the potential triggers sustaining arrhythmic events and recurrences 
in persistent and long standing persistent AF26,27; LAA isolation during 
AF CA has therefore emerged as a procedural answer to this clinical 
observation26-29. One of the possible drawbacks of LAA isolation is 
represented by the possible increased stroke risk due to LAA post 
isolation loss of contractility and mechanical dysfunction26,30, and long 
term OAC is generally recommended (even if a recent retrospective large 
sample study seems to question this risk, reporting a very low long term 
event rate even in the absence of OACs31). LAA concomitant isolation 
and occlusion therefore seemed a reasonable approach to reduce this risk: 
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this approach was first explored and demonstrated in humans by Panikker 
S et al in a propensity-matched interventional study, where they 
suggested that this technique may increase the success of persistent AF 
ablation while obviating the need for chronic OAC32. This combined 
approach appears safe and effective, but still requires larger sample size 
for further validation analysis. To date, no consensus has been yet 
reached in the scientific community on whether or not to routinely 
implement LAA occlusion (staged or concomitant) after LAA isolation: 
expert opinions have both called for a routinely LAAC after isolation33, 
as well as for a case-by-case approach, mainly due to the non-
standardized LAA contractility response to electrical isolation and the 
economical drawbacks34. 
7. Future Directions:  
Combined procedure generally evolves following innovations in the two 
procedural stages that it is composed of. These authors would like to 
highlight some points that to our opinion will represent major hot topics 
in the combined procedure in the future:  
1) Alongside TEE, intra cardiac echography (ICE) has been used and 
described as an effective guidance modality of LAAC; although no RTCs 
TTE vs ICE have been published yet, feasibility and effectiveness has 
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already been reported35-37and this modality will definitely find its way 
also into the LAAC stage of the combined procedure.  
2) Current clinical practice suggests the use of a 60-day post procedural 
regimen of OAC (VKA or NOACs), followed by a 6-month dual anti 
platelet regimen and then lifelong aspirin; the need of OACs at discharge 
has been justified with the increased thrombotic risk posed by the AF 
ablation stage of the procedure. With this regimen, stroke rates in the 
initial follow up phase after combined procedure resulted comparable 
with those reported in cohorts undergoing LAAC procedures alone; 
however, given the high bleeding risk of most candidates to the combined 
procedure, bleeding events during those first 60 days represent one of the 
major issues with the combined procedure22,25. Faster de-escalating 
protocols than those proposed by official occluder devices guidelines 
have already been introduced in LAAC procedure alone for high bleeding 
risk patients38,39; similar lighter post-procedural protocols may be 
evaluated in the combined procedure setting in the near future.  
3) A recent paper from Conti M., et al40 proposed the use of 3D printing 
technology to achieve patient customized occluder devices; although 
being still an embryonal technology, in the near future customized 
occlude devices may become an everyday reality in LAAC and combined 
procedures.  
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4) Ablation related-edema in the LA ridge area, during an extended PVI 
or direct LAA isolation approach, could represent an intra-procedural 
confounding parameter when assessing occluder device size during 
combined procedure. To date, no direct comparison in sizing accuracy 
and peri-device leakage rate between staged and combined procedures 
have been published; further dedicated studies are needed to address the 
magnitude of this problem. 
5) One of the major limitations to the widespread use of the combined 
procedure so far has been its economical drawback: most national health 
care systems, as well as insurance companies, do not reimburse both 
procedures if performed at the same time, making the combined 
procedure an economical pitfall for many institutions. The idea of 
performing LAA occlusion and AF ablation over a 30 days window 
(“Short Interval Stated Procedure”) has been introduced to overcome this 
burden: although similar experiences make perfect sense from an 
economical point of view, they lose the combined procedure main 
advantage of bringing the patient only once into the operating theatre. 
The combined procedure presents an overall cost that is inferior to the 
two independently staged procedure (e.g. single in-hospital stay; single 
use of the OR; less overall procedural time) and it is not unreasonable to 
foresee its economic status recognized in the near future 
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8. Conclusions: 
Today the combined procedure represents a clinical reality in many 
experienced centers and it is usually offered to patients with 
paroxysmal/persistent AF and/or high bleeding risks. Procedural success 
rates are close to 100% and its benefits appear to greatly exceed the low 
peri-procedural complication rate in the hands of experienced operators, 
with an average of a 70% bleeding and stroke risk reduction, regardless 
of the energy source or the occluder device bran employed. The 
combined approach is associated with a reduced risk of new vascular 
access, trans septal puncture and allows to reach a long term OACs 
withdraw of 85+%. However, for the time being, this approach needs to 
be confined to high volume centers and devoted to a very selected patient 
population, until future larger clinical trials will be designed as to 
corroborate the current clinical data. 
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Table 1 – Summary of all combined procedure studies  
 Swaan
s 
Walk
er 
Alipo
ur  
Calv
o 
Phill
ips 
Fassini Wintg
ens L. 
Patients, n  30 26 62 35 98 35 349 
Age 62.8 ± 8.5 
63 ±7 64 ± 
8 
70 ± 
7 
65 
±7 
72 ± 4 63.1 ± 
8.2 
Male 70% 77% 64,5 71% 68% 79% 57.9% 
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% 
Main LAAC reason 
Stroke 
despite 
OAC 
(30%) 
High 
strok
e risk 
(100
%)  
Strok
e 
despi
te 
OAC 
(29%
) 
Majo
r 
bleed
ing 
(48%
) 
High 
strok
e risk 
(100
%) 
Stroke 
despite 
OAC 
(74%) 
Stroke 
despite 
OAC 
(38%) 
Device W W W W or ACP 
W W or 
ACP 
W 
AF type: 
 pxAF, n (%) 
 pAF, n (%) 
 
43% 
57% 
 
54% 
46% 
 
63% 
37% 
 
29% 
71% 
 
57% 
43% 
 
80% 
20% 
 
56% 
44% 
CHA2DS2-VASc 
3 [3 – 
5] 
2,6 
±0.8 
3 
[2.75 
– 4] 
3.1 [2 
– 6] 
2.6 ± 
1 
3 [2 – 5] 3 [2 – 
4] 
HAS-BLED  2 [1 – 
3] 
n.d. 2 [2 – 
3] 
3 [2 – 
6] 
2 [1 
– 3] 
3 [2 – 5] 3 [2 – 
3] 
Procedural Success  100% 100% 100% 97% 100
% 
100% 100% 
PVI energy source 
 
Phased 
RF 
Irriga
ted 
RF 
Phase
d RF 
Irriga
ted 
RF 
Irriga
te RF 
Cryoball
oon 
Irrigat
ed RF 
79% 
Phased 
RF 
21% 
LAAC acute closure 
- Complete 
- Satisfactory 
 
90% 
10% 
 
96% 
4% 
 
87% 
13% 
 
n.d 
 
94% 
6% 
 
86% 
14% 
 
92.6% 
7.4% 
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Peri-procedural 
adverse events 
10% 0% 8.1% 8.5%  8% 11% 7.2% 
FU time, months  12 12 38 
(25 – 
45)  
13 (3 
– 75) 
27±1
4 
24 ± 12 34.5 
(24 – 
44) 
Stroke Annualized 
rate 
0% 0% 1,7% 2.6% 0.5% 0% 0.7% 
Bleeding 10% n.d. 1,7% 2.9% n.d. n.d. 1.1% 
LAAC at First TEE 
- Sealed  
- < 5 mm leak  
- > 5 mm leak  
 
77% 
23% 
0% 
 
77% 
23% 
0% 
 
50% 
45,2
% 
4,8% 
 
97% 
3% 
 
86% 
14% 
 
86% 
14% 
 
70.2% 
28.6% 
1.2% 
Device embolization 3% 0% 1,6% 0 3 0 0.5% 
Device Thrombi 0% 0% 0% 0% 0% 0 1.1% 
AF recurrence rate  30%  23% 42% 22% 46% 29% 51% 
Freedom from OAC 77% 96% 78% 97% n.d. 86% 84.9% 
n.d.: Not Discussed; LAAC: left atrial appendage closure; OAC: oral anti-coagulants; 
W: Watchman; ACP: Amulet Cardiac Plug; pxAF: paroxysmal atrial fibrillation; 
pAF: persistent atrial fibrillation; PVI: pulmonary vein isolation; FU: follow up; TEE: 
trans esophageal echography.  
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Figure 1 – Anti-thrombotic regimen frequencies pre and post combined procedure in 
different studies 
VKA: vitamin K antagonists; DAPT: dual anti platelet; NOACs: non vitamin K 
antagonist oral anti coagulants; SAP: single anti platelet 
 
 
This article is protected by copyright. All rights reserved. 
